Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults

Status Not yet recruiting

Clinical Trial Summary

Phase I safety and dose finding study of a standardized Ayahuasca analog (SM-001) in healthy adult volunteers

Clinical Trial Description

The Investigational New Drug SM-001 is formulated as a hot water decoction of two clonal cultivars of the Peruvian plants, Banisteriopsis caapi (BC) and Psychotria viridis (PV). It represents a modern formulation of an ancient Amazonian botanical medicine, "ayahuasca" ("vine of the soul") that is used by many native South American indigenous and mestizo groups for both religious and medicinal purposes. This initial Phase 1 study is to be conducted as an open label, dose-ranging safety assessment of a single dose of SM-001 taken orally by healthy adult volunteers. Twelve adult men and women, ages 25-65 years, will be consecutively assigned to one of three dose levels, 4 subjects per group (2 M; 2 F). In the presence of the Clinical Investigator(s), each subject will receive a single dose of SM-001, administered at the Clinical Study Site as a liquid at one of three dose levels: 0.25, 0.5, or1.5 ml SM-001 per kg body weight. To assess systemic exposure to SM-001, plasma levels of the four biomarkers, dimethyltryptamine, harmine, tetrahydroharmine, and harmaline will be measured. Blood samples will be drawn at baseline, HR 0 (pre-Study Drug dose), and then at HR 1, 2, 4, 8, and 24 post dose. Subjects will return to the Clinical Study Site at Study Day 28 for a final in-person assessment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05894902
Study type	Interventional
Source	Advanced Integrative Medical Science Institute
Contact	Leanna J Standish, ND PhD
Phone	2064201321
Email	Lstandish@aimsinstitute.net
Status	Not yet recruiting
Phase	Phase 1
Start date	October 1, 2023
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05915013` - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	Phase 1
Recruiting	`NCT05563805` - Exploring Virtual Reality Adventure Training Exergaming	N/A
Recruiting	`NCT05934175` - Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder	N/A
Recruiting	`NCT05934162` - Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD	N/A
Completed	`NCT04460014` - Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT	N/A
Recruiting	`NCT05877807` - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Active, not recruiting	`NCT05992649` - The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject	N/A
Terminated	`NCT04404712` - FAAH Availability in Psychiatric Disorders: A PET Study	Early Phase 1
Not yet recruiting	`NCT05331534` - Effect of Attentional Therapy on Post-traumatic Stress Disorder	N/A
Not yet recruiting	`NCT03649607` - Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black	N/A
Not yet recruiting	`NCT04076215` - Biochemical and Physiological Response to Stressogenic Stimuli	N/A
Not yet recruiting	`NCT02545192` - A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments	Phase 1
Completed	`NCT02329418` - Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit	N/A
Active, not recruiting	`NCT00978484` - A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder	Phase 3
Completed	`NCT00760734` - Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)	Phase 1
Completed	`NCT03278171` - Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
Recruiting	`NCT05874362` - People Bereaved by Violent Death : Negative Event Biases and Temporal Perception	N/A
Terminated	`NCT03898843` - Assisted Animal Therapy: ReAnimal	N/A
Recruiting	`NCT04747379` - Psychological Effect of Explicit Recall After Sedation (PEERS)
Completed	`NCT03248167` - Cannabidiol as a Treatment for AUD Comorbid With PTSD	Phase 1/Phase 2